Facilitation of endothelialization by in situ surface modification

• US 20070100323A1
• Filed: 10/31/2005
• Published: 05/03/2007
• Est. Priority Date: 10/31/2005
• Status: Abandoned Application

• Current Assignee: Advanced Cardiovascular Systems Incorporated
• Original Assignee: Advanced Cardiovascular Systems Incorporated
• Inventors: Ludwig, Florian, EI-Nounou, Fozan, Ahmed Hossainy, Syed, Sharkawy, A.
• Application Number:
  US11/264,514
• Publication Number:
  US 20070100323A1
• Time in Patent Office: Days
• US Class Current: 604/509
• CPC Class Codes: A61L 27/3808 Endothelial cells
• CPC Class Codes: A61L 27/3839 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062

Abstract

A method including delivering to a treatment site within a lumen of a blood vessel (1) a cellular component including at least one of endothelial cells and endothelial progenitor cells and/or (2) a conjugate having a first site having affinity to or capable of conjugating with the blood vessel and a second site having affinity to a cellular component or capable of conjugating with a cellular component. A method including coating a treatment site within a lumen of a blood vessel with a polymeric biomaterial including (1) molecular moieties with affinity to cells or a treatment agent and (2) a treatment agent. A composition including a cellular component including endothelial cells or endothelial progenitor cells and modified to increase the potential for retention at a treatment site. A composition including a polymeric biomaterial including (1) molecular moieties with affinity to cells or a treatment agent or (2) a treatment agent.

Claims

1. A method comprising:

delivering to an treatment site within a lumen of a blood vessel by a percutaneous transluminal route at least one of (1) a cellular component comprising at least one of endothelial cells and endothelial progenitor cells and (2) a conjugate having a first site capable of conjugating with a wall of the blood vessel and a second site capable of conjugating with a cellular component.

2. The method of claim 1, wherein the cellular component that is delivered is modified to increase expression of molecules capable of attaching to a wall of the blood vessel.

3. The method of claim 1, wherein the cellular component that is delivered is packaged in a lipid-philic shell capable of lodging in openings at the injury site.

4. The method of claim 1, wherein the cellular component that is delivered is modified to express or release a treatment agent.

5. The method of claim 4, wherein the treatment agent comprises one of a growth factor and a cytokine.

6. The method of claim 1, wherein the cellular component that is delivered is modified to include a molecule that either alone or in conjunction with a compatible molecule is capable of conjugating the cellular component to a wall of the blood vessel.

7. The method of claim 1, wherein the second site of the conjugate has an affinity for a surface of endothelial progenitor cells.

8. The method of claim 1, wherein prior to delivering the one of the cellular component and the conjugate, the method comprises:

occluding the blood vessel at a point upstream of the injury site.

9. The method of claim 1, wherein prior to delivering the one of the cellular component and the conjugate, the method comprising:

occluding the blood vessel at a point upstream of the injury site and a point downstream of the injury site.

10. The method of claim 1, wherein prior to delivering the one of the cellular component and the conjugate, the method comprises occluding the blood vessel at the injury site with a porous occlusion device, and delivering comprises delivering the treatment agent through the porous occlusion device.

11. The method of claim 1, wherein prior to delivering the at least one of the cellular component and the conjugate, the method comprises inserting an occlusion device into the blood vessel that at least partially occludes the blood vessel, and delivering comprises delivering the agent through the occlusion device.

12. The method of claim 11, wherein the occlusion device comprises a balloon assembly comprising a porous portion and delivering comprises delivering the one of the cellular component and the conjugate through the porous portion.

13. The method of claim 12, wherein a portion of the porous portion is impeded.

14. The method of claim 12, wherein the balloon assembly comprises a non-porous medial working length and a sleeve of a porous material loaded with the at least one of the cellular component and the conjugate.

15. The method of claim 1, wherein prior to delivering the at least one of the cellular component and the conjugate, the method comprises inserting an absorbent device into the blood vessel that is loaded with the at least one of the cellular component and the conjugate.

16. The method of claim 1, wherein prior to delivering the at least one of the cellular component and the conjugate, the method comprises inserting a delivery device into the blood vessel, the deliver device comprising an elongate portion defining an axis and a distal portion coiled at least in part about the axis, the distal portion comprising a plurality of perfusion holes through which the at least one of the cellular component and the conjugate may pass.

17. The method of claim 1, wherein the second site is capable of conjugating with a cellular component comprises an affinity to at least one of CD34 and CD133.

18. A method comprising:

coating a treatment site within a lumen of a blood vessel with a polymeric biomaterial comprising at least one of (1) molecular moieties with affinity to cells or a treatment agent and (2) a treatment agent.

19. The method of claim 18, wherein the treatment agent comprises a property to stimulate migration of cells to the injury site.

20. The method of claim 18, wherein the treatment agent comprises a property to impede migration of cells to the injury site.

21. The method of claim 18, wherein the molecular moieties have an affinity to cells circulating in a blood stream.

22. The method of claim 21, wherein the cells comprise endothelial progenitor cells.

23. The method of claim 18, wherein the treatment agent is formed in a carrier embedded in the biomaterial.

24. A composition comprising:

an amount of a cellular component suitable for delivery into a blood vessel, the cellular component comprising at least one of endothelial cells and endothelial progenitor cells and is modified to increase the potential for retention at a treatment site within the blood vessel.

25. The composition of claim 24, wherein the cellular component is genetically modified to increase expression of molecules capable of attaching to a wall of the blood vessel.

26. The composition of claim 24, wherein the cellular component is modified by packaging in a lipid-philic shell capable of lodging in fissures in a vessel wall at the treatment site.

27. The composition of claim 24, wherein the cellular component is modified to express or release a treatment agent.

28. The composition of claim 27, wherein the treatment agent comprises one of a growth factor and a cytokine.

29. The composition of claim 24, wherein the cellular component is modified to include a molecule that either alone or in conjunction with a compatible molecule is capable of conjugating the cellular component to a wall of the blood vessel.

30. A composition comprising:

a polymeric biomaterial suitable for delivery into a blood vessel, the biomaterial comprising at least one of (1) molecular moieties with affinity to cells or a treatment agent and (2) a treatment agent.

31. The composition of claim 30, wherein the treatment agent comprises one of a growth factor and a cytokine.

32. The composition of claim 30, wherein the treatment agent comprises a property to impede migration of cells to the treatment site.

33. The composition of claim 30, wherein the treatment agent is formed in a carrier embedded in the biomaterial.

34. The composition of claim 30, wherein the biomaterial comprises attachment sites for the treatment agent and the treatment agent has a property to disassociate from the biomaterial over a time period.

36. The composition of claim 30, wherein the molecular moieties have an affinity to cells circulating in a blood stream.

37. The composition of claim 36, wherein the cells are endothelial progenitor cells.

38. The composition of claim 30, wherein the molecular moieties with affinity to cells comprises an affinity to at least one of (1) CD34 and (2) CD133.

39. The composition of claim 30, wherein the treatment agent is formulated in one of a polymeric nanoparticle or microparticle, a lipid or polymer vesicle, and a lipid or polymer micelle.

35. The composition of 30, wherein the treatment agent is chemically conjugated to the biomaterial through a degradable conjugate.